Novartis is planning to give away 100 doses of its hugely expensive spinal muscular atrophy gene therapy Zolgensma in countries outside the US where it is not yet approved, in a controversi
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
